Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,576 shares of common stock on May 6, 2024, to cover withholding tax liabilities related to vested restricted stock units.

Summary

• On May 6, 2024, Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc. (KPTI), sold 3,576 shares of the company's common stock.
• The sale was executed at a price of $1.13 per share.
• Following the transaction, Paulson directly owns 1,153,697 shares of Karyopharm Therapeutics Inc.
• The sale was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax obligations arising from the vesting of restricted stock units.
• The transaction is not a discretionary trade by the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Positives

• The sale was executed under a pre-arranged plan, indicating it was not based on current market sentiment or company performance.
• The CEO still holds a significant number of shares (1,153,697), demonstrating continued investment in the company.

Management Comments

• The sale does not represent a discretionary trade by the reporting person.

Industry Context

Sales of shares to cover tax obligations are a common practice among executives who receive stock-based compensation. This transaction is not necessarily indicative of the executive's view of the company's future prospects.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders due to the slight dilution of equity.
• The transaction is unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates